Urology Products

Solifenacin Succinate 5 mg Tablets

The Primary Treatment for OAB and Urgently Incontinence

The first once-daily, flexible-dose, M3-receptor-selective antimuscarinic for the treatment of OAB

Works by relaxing the muscles in the bladder & Improves ability to control urination

A competitive M3 receptor antimuscarinic agent with a long half-life (45-68 hours)*

Ideally and effectively relieves the symptoms of OAB, with the minimum side effects

Helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom

Offers established long-term safety, efficacy, tolerability and persistence with treatment in 40 week continuation study*

A Time Tasted Tretmant Fer Both Shartandleng Tarm Usase*

.Long-term safety, efficacy, tolerability, and persistence with treatment

have been established in an open label 40-week continuation study**

• Studies have shown that 50% of patients select the higher and lower dose of solifenacin respectively

in the clinical trial setting. Higher doses of solifenacin are not associated with higher rates of discontinuation*

• A large post-marketing head-to-head study comparing solifenacin flexible dose and extended

release tolterodine fixed dose showed a significant benefit of solifenacin treatment***

Therapeutic Indications :

. Symptomatic treatment of urge incontinence

• Increased urinary frequency and urgency with overactive bladder syndrome

*Eur Urol. 2005;47:376-84. Epub 2005 Jan 5.

**Ther Clin Risk Manag. 2008 Feb, 4(1): 117-128